NASDAQ: ANIXAnixa Biosciences Inc Stock
$4.32-0.23 (-5.05%)
Updated Aug 16, 2022
ANIX Price
$4.32
Fair Value Price
$5.24
Market Cap
$131.63M
52 Week Low
$2.30
52 Week High
$5.87
P/E
-8.31x
P/B
4.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$6M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ANIX Overview
Zen Score
–
Industry Average (33)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIX ($4.32) is undervalued by 17.55% relative to our estimate of its Fair Value price of $5.24 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ANIX ($4.32) is not significantly undervalued (17.55%) relative to our estimate of its Fair Value price of $5.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIX due diligence checks available for Premium users.
ANIX News
Valuation
ANIX fair value
Fair Value of ANIX stock based on Discounted Cash Flow (DCF)
Price
$4.32
Fair Value
$5.24
Undervalued by
17.55%
ANIX ($4.32) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIX ($4.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.31x
Industry
-69.87x
Market
32.28x
ANIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.09x
Industry
4.58x
ANIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.5M
Profit Margin
0%
ANIX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$32.8M
Liabilities
$1.4M
Debt to equity
0.04
ANIX's short-term assets ($32.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIX's short-term assets ($32.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$250.0k
Financing
$7.0k
ANIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANIX vs Diagnostic & Research Stocks
Anixa Biosciences Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.